18724359 |
Identification of ALK as a major familial neuroblastoma predisposition gene
Hakonarson, H,
Kim, C,
Speleman, F,
Laureys, G,
Mossé, YP,
Hou, C,
Schork, NJ,
Maris, JM,
Tonini, GP,
Devoto, M,
Attiyeh, EF,
Rappaport, E,
Laudenslager, M,
Cole, KA,
Wood, A,
Lynch, JE,
Sennett, R,
Laquaglia, MJ,
Longo, L,
Torkamani, A,
Perri, P,
Brodeur, GM
|
Nature |
2008 |
29455642 |
Role and targeting of anaplastic lymphoma kinase in cancer
Troiani, T,
Viscardi, G,
Morgillo, F,
Fasano, M,
Martinelli, E,
Ciardiello, F,
Della Corte, CM,
Di Liello, R
|
Mol. Cancer |
2018 |
18923525 |
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Zozulya, S,
George, RE,
Gilliland, DG,
Morris, SW,
Luther, W,
London, WB,
Hanna, M,
Meyerson, M,
McGrady, P,
Sanda, T,
Gregor, VE,
Look, AT,
Zhang, J,
Fröhling, S,
Ahn, Y,
Diller, L,
Webb, TR,
Zhou, W,
Greulich, H,
Gray, NS,
Xue, L
|
Nature |
2008 |
23239810 |
Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors
Ceccon, M,
Mologni, L,
Scapozza, L,
Bisson, W,
Gambacorti-Passerini, C
|
Mol. Cancer Res. |
2013 |
24060861 |
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Palmer, RH,
Hallberg, B
|
Nat. Rev. Cancer |
2013 |
21847362 |
Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer
Lin, SC,
Tu, PH,
Wang, YW,
Lin, KT,
Jou, YS,
Ko, JY
|
Neoplasia |
2011 |
25421750 |
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma
Piazza, R,
Ceccon, M,
Giudici, G,
Mologni, L,
Fontana, D,
Gambacorti-Passerini, C,
Pirola, A
|
Mol. Cancer Res. |
2015 |
18923524 |
Oncogenic mutations of ALK kinase in neuroblastoma
Ohira, M,
Kikuchi, A,
Soda, M,
Kato, M,
Choi, YL,
Nakagawara, A,
Hayashi, Y,
Wang, L,
Ogawa, S,
Chen, Y,
Sanada, M,
Takita, J,
Mano, H,
Igarashi, T
|
Nature |
2008 |